Bruce Neal
A5075162144- Sodium Intake and Health
- Blood Pressure and Hypertension Studies
- Diabetes Treatment and Management
- Nutritional Studies and Diet
- Consumer Attitudes and Food Labeling
- Obesity, Physical Activity, Diet
- Pancreatic function and diabetes
- Global Public Health Policies and Epidemiology
- Diabetes Management and Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Hormonal Regulation and Hypertension
- Acute Ischemic Stroke Management
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Kidney Disease and Diabetes
- Renal function and acid-base balance
- Potassium and Related Disorders
- Heart Failure Treatment and Management
- Lipoproteins and Cardiovascular Health
- Intracerebral and Subarachnoid Hemorrhage Research
- Metabolism, Diabetes, and Cancer
- Medication Adherence and Compliance
- Cardiovascular Health and Disease Prevention
- Diet and metabolism studies
- Cardiovascular Function and Risk Factors
- Cardiac, Anesthesia and Surgical Outcomes
The George Institute for Global Health
2016-2025
The University of Sydney
2016-2025
UNSW Sydney
2015-2025
Imperial College London
2016-2025
George Institute for Global Health
2013-2024
ProCure (United States)
2024
National Health and Medical Research Council
2007-2024
Peking University
2012-2024
Peking University Third Hospital
2024
Stanford Health Care
2023
In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain.We randomly assigned 11,140 diabetes to undergo either standard or control, defined as use gliclazide (modified release) plus other drugs required achieve a glycated hemoglobin value 6.5% less. Primary end points were composites major macrovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke) and microvascular (new worsening nephropathy...
Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment canagliflozin on cardiovascular, renal, safety outcomes.
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials inhibitors sodium–glucose cotransporter (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type diabetes.
<h3>Importance</h3> Elevated systolic blood (SBP) pressure is a leading global health risk. Quantifying the levels of SBP important to guide prevention policies and interventions. <h3>Objective</h3> To estimate association between at least 110 115 mm Hg 140 or higher burden different causes death disability by age sex for 195 countries territories, 1990-2015. <h3>Design</h3> A comparative risk assessment loss related SBP. Estimated distribution was based on 844 studies from 154 (published...
Obstructive sleep apnea is associated with an increased risk of cardiovascular events; whether treatment continuous positive airway pressure (CPAP) prevents major events uncertain.After a 1-week run-in period during which the participants used sham CPAP, we randomly assigned 2717 eligible adults between 45 and 75 years age who had moderate-to-severe obstructive coronary or cerebrovascular disease to receive CPAP plus usual care (CPAP group) alone (usual-care group). The primary composite end...
Whether rapid lowering of elevated blood pressure would improve the outcome in patients with intracerebral hemorrhage is not known.We randomly assigned 2839 who had a spontaneous within previous 6 hours and systolic to receive intensive treatment lower their (with target level <140 mm Hg 1 hour) or guideline-recommended <180 Hg) use agents physician's choosing. The primary was death major disability, which defined as score 3 on modified Rankin scale (in 0 indicates no symptoms, 5 severe...
Severe hypoglycemia may increase the risk of a poor outcome in patients with type 2 diabetes assigned to an intensive glucose-lowering intervention. We analyzed data from large study glucose lowering explore relationship between severe and adverse clinical outcomes.
<h3>Background</h3> High blood pressure and stroke are associated with increased risks of dementia cognitive impairment. This study aimed to determine whether lowering would reduce the decline among individuals cerebrovascular disease. <h3>Methods</h3> The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) was a randomized, double-blind, placebo-controlled trial conducted 6105 people prior or transient ischemic attack. Participants were assigned either active treatment...
There are limited data regarding whether albuminuria and reduced estimated GFR (eGFR) separate independent risk factors for cardiovascular renal events among individuals with type 2 diabetes. The Action in Diabetes Vascular disease: preterAx diamicroN-MR Controlled Evaluation (ADVANCE) study examined the effects of routine BP lowering on adverse outcomes We investigated urinary albumin-to-creatinine ratio (UACR) eGFR 10,640 patients available data. During an average 4.3-yr follow-up, 938...